Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 12, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 12, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 428 Common Stock at $548.13 ($234,599) on October 12, 2026; holds 333,515 after (Indirect).
- Open-market sale: disposed of 1,329 Common Stock at $549.01 ($729,639) on October 12, 2026; holds 332,186 after (Indirect).
- Open-market sale: disposed of 2,565 Common Stock at $550.03 ($1,410,825) on October 12, 2026; holds 329,621 after (Indirect).
- Open-market sale: disposed of 2,628 Common Stock at $551.10 ($1,448,297) on October 12, 2026; holds 326,993 after (Indirect).
- Open-market sale: disposed of 1,857 Common Stock at $551.92 ($1,024,920) on October 12, 2026; holds 325,136 after (Indirect).
- Open-market sale: disposed of 558 Common Stock at $552.93 ($308,535) on October 12, 2026; holds 324,578 after (Indirect).
- Open-market sale: disposed of 135 Common Stock at $554.46 ($74,852) on October 12, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 12, 2026; holds 252,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,231,666 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-12 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-12 | Open-market sale | Common Stock | 428 | $548 | $234.6K | 333,515 |
| 2026-10-12 | Open-market sale | Common Stock | 1,329 | $549 | $729.6K | 332,186 |
| 2026-10-12 | Open-market sale | Common Stock | 2,565 | $550 | $1.4M | 329,621 |
| 2026-10-12 | Open-market sale | Common Stock | 2,628 | $551 | $1.4M | 326,993 |
| 2026-10-12 | Open-market sale | Common Stock | 1,857 | $552 | $1.0M | 325,136 |
| 2026-10-12 | Open-market sale | Common Stock | 558 | $553 | $308.5K | 324,578 |
| 2026-10-12 | Open-market sale | Common Stock | 135 | $554 | $74.9K | 324,443 |
| 2026-10-12 | Option exercise/conversion | Stock Option | 9,500 | — | — | 252,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-12 | Option exercise/conversion (9,500 shares) |
| 2026-10-12 | Open-market sale (428 shares) |
| 2026-10-12 | Open-market sale (1,329 shares) |
| 2026-10-12 | Open-market sale (2,565 shares) |
| 2026-10-12 | Open-market sale (2,628 shares) |
| 2026-10-12 | Open-market sale (1,857 shares) |
| 2026-10-12 | Open-market sale (558 shares) |
| 2026-10-12 | Open-market sale (135 shares) |
| 2026-10-12 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.